Recently, a pause on foreign aid was ordered by Secretary of State Marco Rubio to halt funding for the President’s Emergency Plan for AIDS Relief (PEPFAR) starting Monday, while risking disruption in the supply of anti-retroviral (ARV) drugs to millions.
The local stockpiles may help but uncertainty remains and there are concerns about the potential loss of congressional support following allegations of abortion-related violations. Indian pharmaceutical companies which supply affordable ARVs can be impacted by the stoppage in funding. This pause is part of a broader review of U.S. foreign aid, which is triggered by concerns about contributions from foreign countries.
Here are the Pharma stocks to be affected after Trump Administration to stop AIDS relief funding
Laurus Labs
Laurus Labs is a leading pharmaceutical and biotechnology company, specializing in active pharmaceutical ingredients (APIs) and finished dosage forms, with a focus on generics and contract manufacturing services.
With a market capitalization of Rs 28,642.84 crore, the shares were trading at Rs 531.25 apiece, declining by around 11.64 percent as compared to the previous closing price.
The company’s revenue stood at Rs. 1,415 crore in Q3FY25, during the same period, the net profit stood at Rs. 93 crore.
Cipla
Cipla was founded in 1935. It is a leading Indian multinational pharmaceutical company headquartered in Mumbai while providing over 1,500 affordable healthcare products across 80 countries was focused on various therapeutic areas.
With a market capitalization of Rs 1,12,960 crore, the shares were trading at Rs. 1,398.70 apiece, declining by around 0.93 percent as compared to the previous closing price.
The company’s revenue stood at Rs. 7,051 crore in Q2FY25, during the same period, the net profit stood at Rs. 1,305 crore.
Strides Pharma
Strides Pharma Science Limited was established in 1990 and headquartered in Bangalore which specializes in developing and manufacturing niche generic pharmaceuticals with a global presence across four continents and multiple FDA-approved facilities.
With a market capitalization of Rs. 5,141 crore, the shares were trading at Rs 557.90 apiece, declining by around 8.04 percent as compared to the previous closing price.
The company’s revenue stood at Rs. 1,201 crore in Q2FY25, during the same period, the net profit stood at Rs. 94 crore.
Aurobindo Pharma
Aurobindo Pharma, established in 1986 and headquartered in Hyderabad, India, is a global pharmaceutical company specializing in generic and branded medications across various therapeutic areas, operating in over 150 countries.
With a market capitalization of Rs 68,630.42 crore, the shares were trading at Rs. 1,181.65 apiece, declining by around 2.49 percent as compared to the previous closing price.
The company’s revenue stood at Rs. 7,796 crore in Q2FY25, during the same period, the net profit stood at Rs. 817 crore.
Written by Santhosh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
